Datamonitor Healthcare explores the rationale behind AbbVie’s agreed $54bn acquisition of Shire.
Tax inversion – Re-domiciling in the UK to lower tax burden and improve access to global cash flows.
Portfolio diversification – Diluting Humira dependence with new rare diseases unit and strong pipeline growth
Tax inversion – Re-domiciling in the UK to lower tax burden and improve access to global cash flows.
Portfolio diversification- Diluting Humira dependence with new rare diseases unit and strong pipeline growth
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: